← Leaderboards
Thomas J. Kipps
University Of California San Diego
$21,947,102
Attributed
$21,947,102
Total exposure
23
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.8M · FY2005–24$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$81,458,767 · 24
By mechanism
P01$65,794,891 · 6
R37$4,534,006 · 1
R01$3,805,760 · 2
P30$3,504,856 · 5
U54$2,346,591 · 1
P50$693,826 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California San Diego
Same institution · by research overlap
- Daniel J Donoghue$14,117,426
- Stephen B Howell$14,154,440
- Marcos Intaglietta$17,995,913
- Daniel R Masys$7,925,816
- Dennis A Carson$36,140,483
Others in their field
Top investigators on “Chronic Lymphocytic Leukemia”
- David Heimbrook · Leidos Biomedical Research, Inc.$30,232,142
- Catherine Ju-Ying Wu · Broad Institute, Inc.$27,924,233
- John C Byrd · University Of Cincinnati$23,347,401
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Susan L Slager · Mayo Clinic Rochester$15,712,869
- Brenda J. Weigel · University Of Minnesota$13,972,330
Research focus
Chronic Lymphocytic LeukemiaClinical ResearchCellsLeukemiaHuman SubjectSamplingSignal TransductionProgramsMonitorCd40 MoleculeApoptosisGenesGene ExpressionClinical TrialsResearch PersonnelAntigensNeoplasm /Cancer TherapyTissuesT-LymphocyteGene TherapyHuman Therapy EvaluationLigandsMouse ModelMission
Grant awards (139)
Flow Cytometry Shared Resource$139,670
P30 · FY2024 · CA · contact PI
Hematologic Malignancies$53,141
P30 · FY2024 · CA · contact PI
Non-canonical Wnt-Receptor Signaling and Targeted Therapies$625,253
R01 · FY2023 · CA · contact PI
Flow Cytometry Shared Resource$236,235
P30 · FY2023 · CA · contact PI
Hematologic Malignancies$32,606
P30 · FY2023 · CA · contact PI
Non-canonical Wnt-Receptor Signaling and Targeted Therapies$625,082
R01 · FY2022 · CA · contact PI
Flow Cytometry Shared Resource$236,017
P30 · FY2022 · CA · contact PI
Hematologic Malignancies$30,775
P30 · FY2022 · CA · contact PI
Non-canonical Wnt-Receptor Signaling and Targeted Therapies$638,151
R01 · FY2021 · CA · contact PI
Flow Cytometry Shared Resource$236,146
P30 · FY2021 · CA · contact PI
Hematologic Malignancies$32,589
P30 · FY2021 · CA · contact PI
Non-canonical Wnt-Receptor Signaling and Targeted Therapies$636,298
R01 · FY2020 · CA · contact PI
Flow Cytometry Shared Resource$274,603
P30 · FY2020 · CA · contact PI
Hematologic Malignancies$71,402
P30 · FY2020 · CA · contact PI
Non-canonical Wnt-Receptor Signaling and Targeted Therapies$635,146
R01 · FY2019 · CA · contact PI
Flow Cytometry Shared Resource$249,969
P30 · FY2019 · CA · contact PI
Hematologic Malignancies$32,486
P30 · FY2019 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,883,572
P01 · FY2016 · CA · contact PI
Administrative and Informatics$497,601
P01 · FY2016 · CA · contact PI
Immune Therapy$196,902
P01 · FY2016 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,807,607
P01 · FY2015 · CA · contact PI
Administrative and Informatics$610,335
P01 · FY2015 · CA · contact PI
Immune Therapy$241,511
P01 · FY2015 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,769,923
P01 · FY2014 · CA · contact PI
Administrative and Informatics$604,294
P01 · FY2014 · CA · contact PI
Immune Therapy$239,121
P01 · FY2014 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,655,605
P01 · FY2013 · CA · contact PI
Administrative and Informatics$600,044
P01 · FY2013 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$296,510
R37 · FY2013 · CA · contact PI
Immune Therapy$223,339
P01 · FY2013 · CA · contact PI
FLOW CYTROMETRY$191,816
P30 · FY2013 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,984,569
P01 · FY2012 · CA · contact PI
Administrative and Informatics$638,827
P01 · FY2012 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$318,906
R37 · FY2012 · CA · contact PI
Immune Therapy$252,787
P01 · FY2012 · CA · contact PI
FLOW CYTROMETRY$217,617
P30 · FY2012 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$750,000
P01 · FY2011 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$322,228
R37 · FY2011 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$4,044,476
P01 · FY2010 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$340,333
R37 · FY2010 · CA · contact PI
Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment$339,900
R21 · FY2010 · CA · contact PI
Active Immune Therapy ot Leukemia Associated Antigens and Gene Therapy$297,769
P01 · FY2010 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$116,714
P01 · FY2010 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,970,539
P01 · FY2009 · CA · contact PI
Tumor Therapy/Annihilation Using a Smart NanoPlatform (SNaP)$782,344
U54 · FY2009 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$347,627
R37 · FY2009 · CA · contact PI
Lenalidomide Treatment and the Chronic Lymphocytic Leukemia Microenvironment$339,900
R21 · FY2009 · CA · contact PI
Active Immune Therapy ot Leukemia Associated Antigens and Gene Therapy$293,215
P01 · FY2009 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$113,755
P01 · FY2009 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,860,269
P01 · FY2008 · CA · contact PI
Tumor Therapy/Annihilation Using a Smart NanoPlatform (SNaP)$666,001
U54 · FY2008 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$329,612
R37 · FY2008 · CA · contact PI
Active Immune Therapy ot Leukemia Associated Antigens and Gene Therapy$278,017
P01 · FY2008 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,827,483
P01 · FY2007 · CA · contact PI
Tumor Therapy/Annihilation Using a Smart NanoPlatform (SNaP)$593,977
U54 · FY2007 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$329,612
R37 · FY2007 · CA · contact PI
Active Immune Therapy ot Leukemia Associated Antigens and Gene Therapy$276,593
P01 · FY2007 · CA · contact PI
Chronic Lymphocytic Leukemia Research Consortium$3,956,000
P01 · FY2006 · CA · contact PI
Administrative Core$498,230
P01 · FY2006 · CA · contact PI
Antibody V Gene Expression B Cell Lymphocytic Leukemia$339,457
R37 · FY2006 · CA · contact PI
Active Immune Therapy ot Leukemia Associated Antigens and Gene Therapy$203,931
P01 · FY2006 · CA · contact PI
Tumor Therapy/Annihilation Using a Smart NanoPlatform (SNaP)$174,589
U54 · FY2006 · CA · contact PI
PHASE I/II STUDY OF XCELLERATED T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA$4,205
M01 · FY2006 · RR · contact PI
A CRC PHASE 1 STUDY OF CLOFARABINE FOR TREATMENT OF RELAPSED/REFRACTORY CLL$2,102
M01 · FY2006 · RR · contact PI
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$1,000,000
P01 · FY2005 · CA
Antibody V Gene Expression B Cell Lymphocytic Leukemia$346,594
R37 · FY2005 · CA
Tumor Therapy/Annihilation Using a Smart NanoPlatform (SNaP)$129,680
U54 · FY2005 · CA
PHASE I/II STUDY OF XCELLERATED T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA$36,632
M01 · FY2005 · RR
IMMUNE MONITORING IN B CELL CLL PATIENTS TREATED WITH AD-CD154 CELLS$610
M01 · FY2005 · RR
GX15-070MS EVERY 3 WEEKS FOR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA$610
M01 · FY2005 · RR
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$4,226,576
P01 · FY2004 · CA
Antibody V Gene Expression B Cell Lymphocytic Leukemia$345,469
R37 · FY2004 · CA
Phase I/II Study of Xcellerated T Cells in CLL$54,289
M01 · FY2004 · RR
Immune Monitoring in B Cell CLL Treated with AD-CD154$589
M01 · FY2004 · RR
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$3,640,626
P01 · FY2003 · CA
Competing Supplement for CLL Research Consortium$482,989
P01 · FY2003 · CA
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$263,478
R37 · FY2003 · CA
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$69,920
R37 · FY2003 · CA
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$69,920
R37 · FY2003 · CA
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$3,529,959
P01 · FY2002 · CA
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$256,793
R37 · FY2002 · CA
ERB 2NEU DNA VACCINES FOR BREAST CANCER IMMUNOTHERAPY$220,458
R01 · FY2002 · CA
TRANSLATIONAL ONCOLOGY$183,723
P30 · FY2002 · CA
CORE--FLOW CYTOMETRY FACILITY$183,723
P30 · FY2002 · CA
CORE--FLOW CYTOMETRY FACILITY$183,723
P30 · FY2002 · CA
CORE--FLOW CYTOMETRY FACILITY$183,723
P30 · FY2002 · CA
TRANSLATIONAL ONCOLOGY$183,723
P30 · FY2002 · CA
TRANSLATIONAL ONCOLOGY$183,723
P30 · FY2002 · CA
Immunology of CLL I--Acitive immunotherapy$165,355
P01 · FY2002 · CA
SYNOVIUM AS AN IMMUNE UNDERPRIVILEGED SITE$150,001
P50 · FY2002 · AR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2002 · RR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2002 · RR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2002 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2002 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2002 · RR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2002 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2002 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2002 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2002 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2002 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2002 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2002 · RR
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$3,179,642
P01 · FY2001 · CA
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$252,862
P01 · FY2001 · CA
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$250,301
R37 · FY2001 · CA
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$247,539
P01 · FY2001 · CA
ERB 2NEU DNA VACCINES FOR BREAST CANCER IMMUNOTHERAPY$215,228
R01 · FY2001 · CA
CORE--FLOW CYTOMETRY FACILITY$183,723
P30 · FY2001 · CA
TRANSLATIONAL ONCOLOGY$183,723
P30 · FY2001 · CA
Immunology of CLL I--Acitive immunotherapy$165,355
P01 · FY2001 · CA
SYNOVIUM AS AN IMMUNE UNDERPRIVILEGED SITE$150,001
P50 · FY2001 · AR
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$63,984
R37 · FY2001 · CA
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2001 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2001 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2001 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2001 · RR
CORE--FLOW CYTOMETRY FACILITY$0
P30 · FY2001 · CA
TRANSLATIONAL ONCOLOGY$0
P30 · FY2001 · CA
Immunology of CLL I--Acitive immunotherapy$0
P01 · FY2001 · CA
Immunology of CLL I--Acitive immunotherapy$0
P01 · FY2001 · CA
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2001 · RR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2001 · RR
CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM$3,210,960
P01 · FY2000 · CA
ANTIBODY V GENE EXPRESSION B CELL LYMPHOCYTIC LEUKEMIA$243,262
R37 · FY2000 · CA
ERB 2NEU DNA VACCINES FOR BREAST CANCER IMMUNOTHERAPY$210,144
R01 · FY2000 · CA
SYNOVIUM AS AN IMMUNE UNDERPRIVILEGED SITE$196,912
P50 · FY2000 · AR
SYNOVIUM AS AN IMMUNE UNDERPRIVILEGED SITE$196,912
P50 · FY2000 · AR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2000 · RR
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2000 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2000 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2000 · RR
AUTOIMMUNE HEMOLYTIC ANEMIA AND EXPRESSION OF IG GENES$0
M01 · FY2000 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2000 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2000 · RR
PHASE I STUDY OF CD40 LIGAND TRANSDUCED LEUKEMIA CELLS IN CLL$0
M01 · FY2000 · RR
CORE--FLOW CYTOMETRY FACILITY$0
P30 · FY2000 · CA
TRANSLATIONAL ONCOLOGY--PATHOGENESIS, PROGNOSIS AND GENETIC SUSCEPTIBILITY$0
P30 · FY2000 · CA
Immunology of CLL I--Acitive immunotherapy$0
P01 · FY2000 · CA
GENE TRANSFER OF CD154 INTO MYELOMA PLASMA CELLS$0
M01 · FY2000 · RR